Please fill out the form below and we will gladly respond as soon as possible.
[Philadelphia, PA] The Synovial Sarcoma Foundation (SSF) is honored to welcome Lucia Manzinello Belluco and Roberto Belluco to its Board of Directors as the organization’s first European board members. Their appointment marks an important step in expanding the foundation’s international reach and strengthening collaboration across the global synovial sarcoma community. Lucia brings more than 20 […]
Advances in cell therapy for synovial sarcoma are creating more treatment options for patients with advanced disease. A recent update from Penn Medicine highlights the growing role of T-cell therapies in treating rare cancers like synovial sarcoma. What Is Afami-cel? Afamitresgene autoleucel (afami-cel) is the first FDA-approved T-cell receptor (TCR) therapy for adults with advanced […]
Recent industry analyses suggest the synovial sarcoma treatment market is expected to grow steadily, with projections estimating a compound annual growth rate (CAGR) of approximately 7.9% from 2026 to 2033. While market reports focus on financial trends and market size, they also reflect increasing investment in rare cancer research, drug development pipelines, and emerging therapies. […]